MX2021012129A - Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales. - Google Patents

Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales.

Info

Publication number
MX2021012129A
MX2021012129A MX2021012129A MX2021012129A MX2021012129A MX 2021012129 A MX2021012129 A MX 2021012129A MX 2021012129 A MX2021012129 A MX 2021012129A MX 2021012129 A MX2021012129 A MX 2021012129A MX 2021012129 A MX2021012129 A MX 2021012129A
Authority
MX
Mexico
Prior art keywords
methods
neurodegenerative
compositions
treatment
same
Prior art date
Application number
MX2021012129A
Other languages
English (en)
Inventor
Shawn Johnstone
Robert Devita
Roulet Daniel De
Johan Bartholomeus
Randall Marcelo Chin
Nicholas Thomas Hertz
Original Assignee
Mitokinin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitokinin Inc filed Critical Mitokinin Inc
Publication of MX2021012129A publication Critical patent/MX2021012129A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se dirige a análogos de heteroarilo que contienen nitrógeno, métodos para fabricar los análogos que contienen nitrógeno y métodos para el tratamiento de trastornos relacionados con la actividad de cinasa PINK1 que incluyen, de forma no taxativa, enfermedades neurodegenerativas, enfermedades mitocondriales, fibrosis y/o cardiomiopatías con el uso de estos análogos; este resumen pretende ser una herramienta de lectura rápida para los fines de búsqueda en la técnica particular y no pretende limitar la presente invención.
MX2021012129A 2019-04-03 2020-04-03 Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales. MX2021012129A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962828995P 2019-04-03 2019-04-03
US201962879794P 2019-07-29 2019-07-29
US201962933632P 2019-11-11 2019-11-11
PCT/US2020/026732 WO2020206363A1 (en) 2019-04-03 2020-04-03 Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease

Publications (1)

Publication Number Publication Date
MX2021012129A true MX2021012129A (es) 2022-01-31

Family

ID=72666280

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012129A MX2021012129A (es) 2019-04-03 2020-04-03 Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales.

Country Status (11)

Country Link
US (1) US20220162215A1 (es)
EP (1) EP3947390A4 (es)
JP (1) JP2022527025A (es)
KR (1) KR20220004068A (es)
CN (1) CN114026093A (es)
AU (1) AU2020253561A1 (es)
BR (1) BR112021019802A2 (es)
CA (1) CA3135755A1 (es)
IL (1) IL286767A (es)
MX (1) MX2021012129A (es)
WO (1) WO2020206363A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3067695A1 (en) 2017-06-21 2018-12-27 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
WO2023023671A1 (en) * 2021-08-20 2023-02-23 Mitokinin, Inc. Compositions and methods for treatment of neurodegenerative and mitochondrial disease
WO2023023670A1 (en) * 2021-08-20 2023-02-23 Mitokinin, Inc. Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2429222C2 (ru) * 2006-07-18 2011-09-20 Астеллас Фарма Инк. Аминоиндановое производное или его соль
NZ710444A (en) * 2013-02-11 2020-08-28 Univ California Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
HRP20220759T1 (hr) * 2014-02-11 2022-09-02 Mitokinin, Inc. Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti
CA3067695A1 (en) * 2017-06-21 2018-12-27 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
CN115515682A (zh) * 2020-02-21 2022-12-23 麦托吉宁公司 用于治疗神经退行性疾病和线粒体疾病的组合物及其使用方法

Also Published As

Publication number Publication date
CN114026093A (zh) 2022-02-08
IL286767A (en) 2021-12-01
BR112021019802A2 (pt) 2021-12-07
EP3947390A4 (en) 2022-11-30
EP3947390A1 (en) 2022-02-09
KR20220004068A (ko) 2022-01-11
WO2020206363A1 (en) 2020-10-08
AU2020253561A1 (en) 2021-12-02
JP2022527025A (ja) 2022-05-27
CA3135755A1 (en) 2020-10-08
US20220162215A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
MX2021012129A (es) Composiciones y método para utilizarlas para el tratamiento de enfermedades neurodegenerativas y mitocondriales.
SA521430638B1 (ar) H مركبات بيرميدين-2-يل أمينو-1 lrrk2 بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبية
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
PH12016501600A1 (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
EA202091709A1 (ru) Ингибиторы днк-пк
MX2018006195A (es) Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk.
MX2017016424A (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares.
EA201790818A1 (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы bace1
EA201791802A1 (ru) СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС
PH12017501043A1 (en) 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
MX2022006466A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activacion inmune.
EA202091708A1 (ru) Ингибиторы днк-пк
EA201892098A1 (ru) Соединение, обладающее ингибирующей мутантную idh активностью, способ его получения и применения
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
ZA202210409B (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
MX2018007511A (es) Compuestos de alquinil dihidroquinolina sulfonamida.
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
MX2021011574A (es) Nuevos compuestos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios.
MX2021008081A (es) Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa.
MX2020011766A (es) Metodos de administracion de tratamiento antifibrotico.
MX2020007162A (es) Metodos para el tratamiento de trastornos del desarrollo y/o trastornos convulsivos con etifoxina.
MX2020001199A (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas.
EA201690170A1 (ru) Композиции и способы для лечения инсульта